Cargando…
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CA...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/ https://www.ncbi.nlm.nih.gov/pubmed/35456250 http://dx.doi.org/10.3390/jcm11082158 |
_version_ | 1784690667784503296 |
---|---|
author | Boettcher, Michael Joechner, Alexander Li, Ziduo Yang, Sile Fiona Schlegel, Patrick |
author_facet | Boettcher, Michael Joechner, Alexander Li, Ziduo Yang, Sile Fiona Schlegel, Patrick |
author_sort | Boettcher, Michael |
collection | PubMed |
description | CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information. |
format | Online Article Text |
id | pubmed-9024694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90246942022-04-23 Development of CAR T Cell Therapy in Children—A Comprehensive Overview Boettcher, Michael Joechner, Alexander Li, Ziduo Yang, Sile Fiona Schlegel, Patrick J Clin Med Review CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information. MDPI 2022-04-12 /pmc/articles/PMC9024694/ /pubmed/35456250 http://dx.doi.org/10.3390/jcm11082158 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Boettcher, Michael Joechner, Alexander Li, Ziduo Yang, Sile Fiona Schlegel, Patrick Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title | Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title_full | Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title_fullStr | Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title_full_unstemmed | Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title_short | Development of CAR T Cell Therapy in Children—A Comprehensive Overview |
title_sort | development of car t cell therapy in children—a comprehensive overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/ https://www.ncbi.nlm.nih.gov/pubmed/35456250 http://dx.doi.org/10.3390/jcm11082158 |
work_keys_str_mv | AT boettchermichael developmentofcartcelltherapyinchildrenacomprehensiveoverview AT joechneralexander developmentofcartcelltherapyinchildrenacomprehensiveoverview AT liziduo developmentofcartcelltherapyinchildrenacomprehensiveoverview AT yangsilefiona developmentofcartcelltherapyinchildrenacomprehensiveoverview AT schlegelpatrick developmentofcartcelltherapyinchildrenacomprehensiveoverview |